Found 4363 articles for: ""
A Randomized Control Trial Comparing the Efficacy of Platelet-Rich Plasma and 5% Topical Minoxidil for the Treatment of Androgenetic Alopecia
September 2023 | Volume 22 | Issue 9 | Original Article | 905 | Copyright © September 2023
Androgenetic alopecia (AGA) is the most common cause of hair loss in men and has limited treatment options. Minoxidil is a common therapeutic option for AGA patients because of its availability. Plate...
Read MoreClinical Trial of Alpha and Beta Defensin Skin Care Regimen for Improvement of Periocular Wrinkles
September 2023 | Volume 22 | Issue 9 | Original Article | 874 | Copyright © September 2023
Background: Defensins recruit leucine-rich repeat-containing G protein-coupled receptor 6 positive (Lgr6+) stem cells which ultimately regenerate new basal stem cells, healthy ke...
Read MoreInto the Light: Afamelanotide and the Treatment of Erythropoietic Protoporphyria in the United States
September 2023 | Volume 22 | Issue 9 | Original Article | 941 | Copyright © September 2023
Background: Erythropoietic protoporphyria (EPP) is a rare disease that causes disabling cutaneous photosensitivity with pain and burning sensations. In 2019, afamelanotide, an &a...
Read MoreEvaluation of a Neck Cream Developed to Enhance Nitric Oxide Availability in Aging Skin
September 2023 | Volume 22 | Issue 9 | Original Article | 881 | Copyright © September 2023
Background: To meet the unique needs of aging skin of the neck, a new neck cream that enhances nitric oxide availability has been developed to visibly improve signs of aging and ...
Read MoreFULL SUPPLEMENT: Management of Atopic Dermatitis in People with Skin of Color: A Practical Algorithm
August 2023 | Volume 22 | Issue 8 | Department | SF386361s1 | Copyright © August 2023
Background: Variations in the epidemiology, clinical presentation, and disease course in skin of color (SOC) atopic dermatitis (AD) patients have been reported that may impact treatme...
Read MoreFULL SUPPLEMENT: Fixed Combination Calcipotriene/Betamethasone (Cal/BDP) Cream: Evaluating the Role of Polyaphron Dispersion (PAD) Technology in Psoriasis Treatment
August 2023 | Volume 22 | Issue 8 | Department | SF381621s1 | Copyright © August 2023
Most patients with plaque psoriasis exhibit mild-to-moderate disease and topical therapies remain the mainstay treatment option for these patients. The use of topical steroids in combination with vita...
Read MoreOff-Label Use of Baricitinib in Dermatology
August 2023 | Volume 22 | Issue 8 | Original Article | 795 | Copyright © August 2023
The current US Food and Drug Administration (FDA) indications for baricitinib include alopecia areata, rheumatoid arthritis, and COVID-19. However, increasing evidence indicates that baricitinib ...
Read MoreNo Racial Differences Found in Access to Biologics: A Population-Based Study of Psoriasis Patients in the United States
August 2023 | Volume 22 | Issue 8 | Editorials | 835 | Copyright © August 2023
Background: Conflicting evidence exists regarding the role of race in access to biologics for patients with psoriasis. Objective: To compare biologic use among adult and pediatric Uni...
Read MoreINDIVIDUAL ARTICLE: An Algorithm for the Management of Atopic Dermatitis in People With Skin of Color
August 2023 | Volume 22 | Issue 8 | Supplement Individual Articles | SF386361s3 | Copyright © August 2023
Background: Variations in the epidemiology, clinical presentation, and disease course in skin of color (SOC) atopic dermatitis (AD) patients have been reported that may impact tr...
Read MoreEXTRA, EXTRA, Treatment Approaches for EXTRAmammary Paget Disease
August 2023 | Volume 22 | Issue 8 | Features | 844 | Copyright © August 2023
Desai S, McCormick E, Nelson K, et al. EXTRA, EXTRA, treatment approaches for EXTRAmammary Paget disease. J Drugs Dermatol. 2023;22(8):844-845. doi:10.36849/JDD.2023.NVRN0823...
Read MoreINDIVIDUAL ARTICLE: Fixed Combination Calcipotriene/Betamethasone (Cal/BDP) Cream: Evaluating the Role of Polyaphron Dispersion (PAD) Technology in Psoriasis Treatment
August 2023 | Volume 22 | Issue 8 | Supplement Individual Articles | SF381621s5 | Copyright © August 2023
Most patients with plaque psoriasis exhibit mild-to-moderate disease and topical therapies remain the mainstay treatment option for these patients. The use of topical steroids in combination with...
Read MoreDermatology in Contemporary Times: Building Awareness of Social Media's Association With Adolescent Skin Disease and Mental Health
August 2023 | Volume 22 | Issue 8 | Original Article | 817 | Copyright © August 2023
Background: The contribution of psychological disorders to the burden of skin disease has been poorly explored in adolescent patients. The review aims to provide insights into the psychological, socia...
Read MoreLong-Term Safety and Efficacy of Twice-Daily Topical Clascoterone Cream 1% in Patients Greater Than or Equal to 12 Years of Age With Acne Vulgaris
August 2023 | Volume 22 | Issue 8 | Original Article | 810 | Copyright © August 2023
Background: Clascoterone cream 1% is approved for the treatment of acne vulgaris in patients aged ≥ 12 years based on results from two 12-week Phase 3 studies in patients with...
Read MoreDiagnosis and Management of Pediatric Psoriasis: An Overview for Pediatricians
August 2023 | Volume 22 | Issue 8 | Original Article | 742 | Copyright © August 2023
Pediatric psoriasis (PsO) and its associated comorbidities carry physical and psychosocial burdens in children and adolescents, which can negatively impact quality of life. However, features dist...
Read MoreConsensus Statements on the Use of Corticosteroid-Containing Topical Medications in Psoriasis
August 2023 | Volume 22 | Issue 8 | Original Article | 736 | Copyright © August 2023
This article aims to provide consensus statements on the use of corticosteroid-containing topical medications for the management of psoriasis. This Psoriasis Expert Group (PEG) includes dermatolo...
Read MorePsoriasis and Skin Barrier Dysfunction: The Role of Gentle Cleansers and Moisturizers in Treating Psoriasis
August 2023 | Volume 22 | Issue 8 | Original Article | 773 | Copyright © August 2023
Background: Psoriasis is a chronic immune-mediated dermatologic disorder with multisystemic comorbidities, which is effectively treated with a range of prescription therapies. St...
Read MoreTildrakizumab in Combination With Topical Halcinonide 0.1% Ointment for Treating Moderate to Severe Plaque Psoriasis
August 2023 | Volume 22 | Issue 8 | Original Article | 766 | Copyright © August 2023
Background: This prospective, open-label study evaluated the effectiveness and safety of tildrakizumab plus topical halcinonide ointment in psoriasis patients.Read More The Patient-Physician Relationship and Adherence: Observations From a Clinical Study
August 2023 | Volume 22 | Issue 8 | Editorials | 838 | Copyright © August 2023
Improved patient-physician relationships (PPR) are associated with better patient satisfaction and disease outcomes, however, there is limited literature assessing how PPR affects adherence in de...
Read MoreAntimalarials are not Effective as Pre-Exposure Prophylaxis for COVID-19: A Retrospective Matched Control Study
August 2023 | Volume 22 | Issue 8 | Editorials | 840 | Copyright © August 2023
The early phase of the COVID-19 pandemic prompted a repurposing of antiviral and immunomodulatory drugs as investigational therapeutics, including hydroxychloroquine and chloroquine. While antima...
Read MoreRethinking the Inflammatory Balance in Psoriasis and Atherosclerosis
August 2023 | Volume 22 | Issue 8 | Features | 832 | Copyright © August 2023
Guénin S, Kazemi A, Cline A, et al. Rethinking the inflammatory balance in psoriasis and atherosclerosis. J Drugs Dermatol. 2023;22(8):832-833. doi:10.36849/JDD.7082...
Read MoreMedia and other results for: ""